JP2008528466A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008528466A5 JP2008528466A5 JP2007551740A JP2007551740A JP2008528466A5 JP 2008528466 A5 JP2008528466 A5 JP 2008528466A5 JP 2007551740 A JP2007551740 A JP 2007551740A JP 2007551740 A JP2007551740 A JP 2007551740A JP 2008528466 A5 JP2008528466 A5 JP 2008528466A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound according
- disease
- condition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 5
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000029742 colonic neoplasm Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 210000001685 thyroid gland Anatomy 0.000 claims description 3
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims description 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 208000003950 B-cell lymphoma Diseases 0.000 claims description 2
- 108091007914 CDKs Proteins 0.000 claims description 2
- 208000017604 Hodgkin disease Diseases 0.000 claims description 2
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 claims description 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
- 201000010208 Seminoma Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010042971 T-cell lymphoma Diseases 0.000 claims description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 2
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000007455 central nervous system cancer Diseases 0.000 claims description 2
- 208000025997 central nervous system neoplasm Diseases 0.000 claims description 2
- 201000010881 cervical cancer Diseases 0.000 claims description 2
- 210000003679 cervix uteri Anatomy 0.000 claims description 2
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 2
- 210000002615 epidermis Anatomy 0.000 claims description 2
- 210000003238 esophagus Anatomy 0.000 claims description 2
- 210000000232 gallbladder Anatomy 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 210000001672 ovary Anatomy 0.000 claims description 2
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 210000002784 stomach Anatomy 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 208000001608 teratocarcinoma Diseases 0.000 claims description 2
- 201000002510 thyroid cancer Diseases 0.000 claims description 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 13
- 239000003814 drug Substances 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 3
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 201000004101 esophageal cancer Diseases 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- -1 2,6-dichlorophenyl Chemical group 0.000 claims 1
- CCUXEBOOTMDSAM-UHFFFAOYSA-N 4-[(2,6-dichlorobenzoyl)amino]-n-(1-methylsulfonylpiperidin-4-yl)-1h-pyrazole-5-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCC1NC(=O)C1=C(NC(=O)C=2C(=CC=CC=2Cl)Cl)C=NN1 CCUXEBOOTMDSAM-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 claims 1
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061534 Oesophageal squamous cell carcinoma Diseases 0.000 claims 1
- 208000036765 Squamous cell carcinoma of the esophagus Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000007276 esophageal squamous cell carcinoma Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 210000002768 hair cell Anatomy 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000002429 large intestine Anatomy 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 201000003883 Cystic fibrosis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000032382 Ischaemic stroke Diseases 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 229940043378 cyclin-dependent kinase inhibitor Drugs 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 208000002320 spinal muscular atrophy Diseases 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64621705P | 2005-01-21 | 2005-01-21 | |
| GB0501480A GB0501480D0 (en) | 2005-01-22 | 2005-01-22 | Pharmaceutical compounds |
| GB0501748A GB0501748D0 (en) | 2005-01-27 | 2005-01-27 | Pharmaceutical compounds |
| US65133905P | 2005-02-09 | 2005-02-09 | |
| PCT/GB2006/000193 WO2006077416A1 (en) | 2005-01-21 | 2006-01-20 | Pyrazole derivatives for the inhibition of cdk' s and gsk' s |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008528466A JP2008528466A (ja) | 2008-07-31 |
| JP2008528466A5 true JP2008528466A5 (enExample) | 2009-03-12 |
Family
ID=35967182
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551740A Withdrawn JP2008528466A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋ阻害ピラゾール誘導体 |
| JP2007551739A Pending JP2008528465A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
| JP2007551742A Pending JP2008528467A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007551739A Pending JP2008528465A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
| JP2007551742A Pending JP2008528467A (ja) | 2005-01-21 | 2006-01-20 | Ｃｄｋおよびｇｓｋの阻害のためのピラゾール誘導体 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20080194562A1 (enExample) |
| EP (3) | EP1853584A1 (enExample) |
| JP (3) | JP2008528466A (enExample) |
| KR (3) | KR20070098928A (enExample) |
| AR (3) | AR052559A1 (enExample) |
| AU (3) | AU2006207311A1 (enExample) |
| BR (2) | BRPI0606107A2 (enExample) |
| CA (3) | CA2593465A1 (enExample) |
| IL (3) | IL184499A0 (enExample) |
| MA (3) | MA29254B1 (enExample) |
| MX (3) | MX2007008782A (enExample) |
| NO (3) | NO20073960L (enExample) |
| PE (3) | PE20060876A1 (enExample) |
| TN (3) | TNSN07279A1 (enExample) |
| WO (3) | WO2006077414A1 (enExample) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2532965C (en) * | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| TW200533657A (en) | 2004-02-17 | 2005-10-16 | Esteve Labor Dr | Substituted pyrazoline compounds, their preparation and use as medicaments |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| KR101345002B1 (ko) * | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| KR101346886B1 (ko) * | 2005-01-21 | 2014-01-02 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| US8404718B2 (en) | 2005-01-21 | 2013-03-26 | Astex Therapeutics Limited | Combinations of pyrazole kinase inhibitors |
| EP1862478B1 (en) * | 2005-03-03 | 2012-01-25 | Mitsubishi Rayon Co., Ltd. | Polymer particle, resin composition containing same, and molded body |
| EP1743890A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios Del Dr. Esteve, S.A. | 4,5-Dihydro-1H-pyrazole derivatives, their preparation and use as medicaments |
| EP1743892A1 (en) | 2005-07-15 | 2007-01-17 | Laboratorios del Dr. Esteve S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| US7897589B2 (en) | 2005-07-15 | 2011-03-01 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
| JP2009536187A (ja) * | 2006-05-05 | 2009-10-08 | アステックス・セラピューティクス・リミテッド | 癌の処置のための４−（２，６−ジクロロ−ベンゾイルアミノ）−１ｈ−ピラゾール−３−カルボン酸（１−メタンスルホニル−ピペリジン−４−イル）−アミド |
| WO2007129062A1 (en) * | 2006-05-08 | 2007-11-15 | Astex Therapeutics Limited | Pharmaceutical combinations of diazole derivatives for cancer treatment |
| EP2046330A2 (en) * | 2006-07-14 | 2009-04-15 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP2009543771A (ja) * | 2006-07-14 | 2009-12-10 | アステックス・セラピューティクス・リミテッド | 医薬化合物 |
| WO2008009954A1 (en) * | 2006-07-21 | 2008-01-24 | Astex Therapeutics Limited | Medical use of cyclin dependent kinases inhibitors |
| WO2008023720A1 (en) * | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| JP5528806B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| CA2667720A1 (en) * | 2006-11-09 | 2008-05-15 | Abbott Gmbh & Co. Kg. | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| FR2908409B1 (fr) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
| FR2913018A1 (fr) * | 2007-02-23 | 2008-08-29 | Sanofi Aventis Sa | Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs |
| EP2267459A1 (en) * | 2009-06-25 | 2010-12-29 | Universite Pierre Et Marie Curie - Paris VI | Method for determining the susceptibility of a cell strain to drugs |
| CA2834049C (en) | 2011-04-25 | 2018-05-22 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| DE102011106990B3 (de) * | 2011-07-08 | 2013-01-03 | Technische Universität Darmstadt | Verbindungen als Glykogen Synthase Kinase 3 (GSK-3) Inhibitoren für die Behandlung von GSK-3-vermittelten Erkrankungen |
| BRPI1107312B1 (pt) | 2011-11-25 | 2021-09-08 | Universidade Federal De Santa Catarina | Composto de acil-hidrazona |
| MX351287B (es) * | 2012-02-21 | 2017-10-09 | Acraf | Compuestos de 1h-indazol-3-carboxamida como inhibidores de glucogeno sintasa quinasa 3 beta. |
| EP2825886A4 (en) * | 2012-03-14 | 2015-11-18 | Stephen Marx | MEDIUM AND METHODS OF DIAGNOSIS AND THERAPY OF ILLNESSES |
| US8765762B2 (en) | 2012-10-25 | 2014-07-01 | Usher III, Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degerative diseases and hearing loss associated with usher syndrome |
| CA2889537C (en) * | 2012-10-25 | 2017-12-12 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| US9227976B2 (en) | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| US9409895B2 (en) | 2012-12-19 | 2016-08-09 | Novartis Ag | Autotaxin inhibitors |
| CN104968656B (zh) | 2012-12-19 | 2017-08-11 | 诺华股份有限公司 | 自分泌运动因子抑制剂 |
| JP5651812B1 (ja) | 2013-04-25 | 2015-01-14 | 杏林製薬株式会社 | 固形医薬組成物 |
| WO2014179144A1 (en) * | 2013-04-29 | 2014-11-06 | E. I. Du Pont De Nemours And Company | Fungicidal heterocyclic compounds |
| EP2980088A1 (en) | 2014-07-28 | 2016-02-03 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| WO2015113927A1 (en) * | 2014-01-29 | 2015-08-06 | Bayer Pharma Aktiengesellschaft | Amino-substituted isothiazoles |
| JP2017528460A (ja) * | 2014-09-10 | 2017-09-28 | エピザイム インコーポレイテッド | 不可逆的ｓｍｙｄ阻害剤としてのイソオキサゾールカルボキサミド |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CA2978518C (en) | 2015-03-27 | 2023-11-21 | Nathanael S. Gray | Inhibitors of cyclin-dependent kinases |
| TWI730959B (zh) | 2015-05-19 | 2021-06-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺 |
| WO2019188207A1 (ja) | 2018-03-27 | 2019-10-03 | ダイキン工業株式会社 | 電解液、電気化学デバイス、リチウムイオン二次電池、モジュール及び化合物 |
| WO2019188210A1 (ja) | 2018-03-27 | 2019-10-03 | ダイキン工業株式会社 | 電解液、電気化学デバイス、リチウムイオン二次電池及びモジュール |
| WO2019188200A1 (ja) | 2018-03-27 | 2019-10-03 | ダイキン工業株式会社 | スルファミン酸リチウムの製造方法及び新規スルファミン酸リチウム |
| WO2020005807A1 (en) * | 2018-06-25 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Taire family kinase inhibitors and uses thereof |
| EP3902542A4 (en) | 2018-12-28 | 2022-09-07 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| CN111848579B (zh) | 2019-04-26 | 2023-11-14 | 君实润佳(上海)医药科技有限公司 | 4-(2,6-二氯苯甲酰氨基)-n-(4-哌啶基)-1h-吡唑-3-甲酰胺的前药 |
| US12097261B2 (en) | 2021-05-07 | 2024-09-24 | Kymera Therapeutics, Inc. | CDK2 degraders and uses thereof |
| WO2023072096A1 (zh) * | 2021-10-25 | 2023-05-04 | 优领医药科技(香港)有限公司 | 含四氢呋喃多环类衍生物、其药学上可接受的盐及其制备方法和应用 |
| WO2023154426A1 (en) * | 2022-02-11 | 2023-08-17 | Relay Therapeutics, Inc. | Cdk inhibitors and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4282361A (en) * | 1978-03-16 | 1981-08-04 | Massachusetts Institute Of Technology | Synthesis for 7-alkylamino-3-methylpyrazolo [4,3-d]pyrimidines |
| US5502068A (en) * | 1995-01-31 | 1996-03-26 | Synphar Laboratories, Inc. | Cyclopropylpyrroloindole-oligopeptide anticancer agents |
| WO1997027852A1 (en) * | 1996-01-30 | 1997-08-07 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6020357A (en) * | 1996-12-23 | 2000-02-01 | Dupont Pharmaceuticals Company | Nitrogen containing heteroaromatics as factor Xa inhibitors |
| US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
| AU2001241128A1 (en) * | 2000-03-14 | 2001-09-24 | Fujisawa Pharmaceutical Co. Ltd. | Novel amide compounds |
| US6455559B1 (en) * | 2001-07-19 | 2002-09-24 | Pharmacia Italia S.P.A. | Phenylacetamido-pyrazole derivatives, process for their preparation and their use as antitumor agents |
| US20050119305A1 (en) * | 2001-03-21 | 2005-06-02 | Masao Naka | Il-6 production inhibitors |
| GB0218625D0 (en) * | 2002-08-10 | 2002-09-18 | Astex Technology Ltd | Pharmaceutical compounds |
| US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
| US7320989B2 (en) * | 2003-02-28 | 2008-01-22 | Encysive Pharmaceuticals, Inc. | Pyridine, pyrimidine, quinoline, quinazoline, and naphthalene urotensin-II receptor antagonists |
| TWI372050B (en) * | 2003-07-03 | 2012-09-11 | Astex Therapeutics Ltd | (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles |
| CA2532965C (en) * | 2003-07-22 | 2013-05-14 | Astex Therapeutics Limited | 3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators |
| KR101346886B1 (ko) * | 2005-01-21 | 2014-01-02 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
| US20080161355A1 (en) * | 2005-01-21 | 2008-07-03 | Astex Therapeutics Limited | Combinations of Pyrazole Kinase Inhibitors and Further Antitumor Agents |
| AR052559A1 (es) * | 2005-01-21 | 2007-03-21 | Astex Therapeutics Ltd | Derivados de pirazol para inhibir cdk's y gsk's |
| US20080139620A1 (en) * | 2005-01-21 | 2008-06-12 | Astex Therapeutics Limited | Pyrazole Derivatives For The Inhibition Of Cdk's And Gsk's |
| AR054425A1 (es) * | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| KR101345002B1 (ko) * | 2005-01-21 | 2013-12-31 | 아스텍스 테라퓨틱스 리미티드 | 제약 화합물 |
-
2006
- 2006-01-19 AR ARP060100204A patent/AR052559A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100202A patent/AR053662A1/es not_active Application Discontinuation
- 2006-01-19 AR ARP060100205A patent/AR052660A1/es not_active Application Discontinuation
- 2006-01-20 CA CA002593465A patent/CA2593465A1/en not_active Abandoned
- 2006-01-20 CA CA002593468A patent/CA2593468A1/en not_active Abandoned
- 2006-01-20 KR KR1020077018917A patent/KR20070098928A/ko not_active Withdrawn
- 2006-01-20 KR KR1020077018916A patent/KR20070098927A/ko not_active Withdrawn
- 2006-01-20 PE PE2006000079A patent/PE20060876A1/es not_active Application Discontinuation
- 2006-01-20 WO PCT/GB2006/000191 patent/WO2006077414A1/en not_active Ceased
- 2006-01-20 JP JP2007551740A patent/JP2008528466A/ja not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000196 patent/WO2006077419A1/en not_active Ceased
- 2006-01-20 JP JP2007551739A patent/JP2008528465A/ja active Pending
- 2006-01-20 KR KR1020077018915A patent/KR20070107049A/ko not_active Withdrawn
- 2006-01-20 BR BRPI0606107-9A patent/BRPI0606107A2/pt not_active IP Right Cessation
- 2006-01-20 PE PE2006000080A patent/PE20061073A1/es not_active Application Discontinuation
- 2006-01-20 MX MX2007008782A patent/MX2007008782A/es not_active Application Discontinuation
- 2006-01-20 PE PE2006000081A patent/PE20061198A1/es not_active Application Discontinuation
- 2006-01-20 US US11/814,446 patent/US20080194562A1/en not_active Abandoned
- 2006-01-20 EP EP06704677A patent/EP1853584A1/en not_active Withdrawn
- 2006-01-20 WO PCT/GB2006/000193 patent/WO2006077416A1/en not_active Ceased
- 2006-01-20 JP JP2007551742A patent/JP2008528467A/ja active Pending
- 2006-01-20 AU AU2006207311A patent/AU2006207311A1/en not_active Abandoned
- 2006-01-20 EP EP06709562A patent/EP1846395A1/en not_active Withdrawn
- 2006-01-20 CA CA002593656A patent/CA2593656A1/en not_active Abandoned
- 2006-01-20 MX MX2007008784A patent/MX2007008784A/es not_active Application Discontinuation
- 2006-01-20 AU AU2006207316A patent/AU2006207316A1/en not_active Abandoned
- 2006-01-20 US US11/814,443 patent/US20080306069A1/en not_active Abandoned
- 2006-01-20 EP EP06700940A patent/EP1853600A1/en not_active Withdrawn
- 2006-01-20 AU AU2006207313A patent/AU2006207313A1/en not_active Abandoned
- 2006-01-20 BR BRPI0606317-9A patent/BRPI0606317A2/pt not_active IP Right Cessation
- 2006-01-20 MX MX2007008780A patent/MX2007008780A/es not_active Application Discontinuation
-
2007
- 2007-07-09 IL IL184499A patent/IL184499A0/en unknown
- 2007-07-09 IL IL184502A patent/IL184502A0/en unknown
- 2007-07-09 IL IL184503A patent/IL184503A0/en unknown
- 2007-07-20 TN TNP2007000279A patent/TNSN07279A1/en unknown
- 2007-07-20 TN TNP2007000278A patent/TNSN07278A1/en unknown
- 2007-07-20 TN TNP2007000281A patent/TNSN07281A1/en unknown
- 2007-07-27 NO NO20073960A patent/NO20073960L/no not_active Application Discontinuation
- 2007-07-27 NO NO20073955A patent/NO20073955L/no not_active Application Discontinuation
- 2007-07-27 NO NO20073956A patent/NO20073956L/no not_active Application Discontinuation
- 2007-08-16 MA MA30144A patent/MA29254B1/fr unknown
- 2007-08-16 MA MA30143A patent/MA29253B1/fr unknown
- 2007-08-16 MA MA30145A patent/MA29255B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008528466A5 (enExample) | ||
| US9284298B2 (en) | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | |
| JP6959248B2 (ja) | 癌治療用の４，６−ジヒドロピロロ［３，４−ｃ］ピラゾール−５（１Ｈ）−カルボニトリル誘導体 | |
| KR102001745B1 (ko) | 키나제 억제제로서 유용한 인돌 카르복스아미드 화합물 | |
| EP2699564B1 (en) | Substituted pyrimidinyl-pyrroles active as kinase inhibitors | |
| EP1043998B1 (en) | USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDANT KINASE INHIBITORS | |
| JP5703212B2 (ja) | キナーゼ阻害剤としてのピロロピリジン | |
| JP2016527263A5 (enExample) | ||
| JP2020143124A (ja) | Ｕｓｐ３０阻害剤としての１−シアノ−ピロリジン化合物 | |
| RU2019101002A (ru) | Производные n-(замещенный фенил)-сульфонамида в качестве ингибиторов киназы | |
| CZ297907B6 (cs) | Aminothiazolové deriváty a farmaceutické kompozice s jejich obsahem | |
| UA114178C2 (uk) | Комбінація, що включає інгібітор cdk4/6 і інгібітор pi3k, для лікування раку | |
| CN103003280A (zh) | 作为cdk4/6抑制剂的氘化吡咯并嘧啶化合物 | |
| WO2014019908A2 (en) | Substituted pyrroles active as kinases inhibitors | |
| JP2016525078A5 (enExample) | ||
| JP2017537946A5 (enExample) | ||
| JP2008505167A5 (enExample) | ||
| JP6592512B2 (ja) | 三環式アトロプ異性体の化合物 | |
| WO2017049462A1 (zh) | 一类新型的flt3激酶抑制剂及其用途 | |
| CN106456639B (zh) | Hiv逆转录酶抑制剂的前药 | |
| Elagawany et al. | Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors | |
| KR101129088B1 (ko) | Ｎ-［6-(시스-2,6-디메틸모르폴린-4-일)피리딘-3-일］-2-메틸-4'-(트리플루오로메톡시)［1,1'-비페닐］-3-카르복스아미드의 염 | |
| CN115956070A (zh) | 磺酰胺化合物 | |
| EP3372589B1 (en) | Pyrimidine derivative | |
| JP2014522836A (ja) | 併用療法 |